Literature DB >> 28578117

Pipeline Embolization Device in Treatment of 50 Unruptured Large and Giant Aneurysms.

Nimer Adeeb1, Christoph J Griessenauer1, Hussain Shallwani2, Hakeem Shakir2, Paul M Foreman3, Justin M Moore1, Adam A Dmytriw1, Raghav Gupta1, Adnan H Siddiqui2, Elad I Levy2, Kenneth Snyder2, Mark R Harrigan3, Christopher S Ogilvy1, Ajith J Thomas4.   

Abstract

INTRODUCTION: Treatment of large (≥20 mm) and giant (≥25 mm) intracranial aneurysms is challenging and can be associated with a high rate of morbidity and mortality. The Pipeline Embolization Device (PED) has been used effectively for the treatment of intracranial aneurysms achieving a high rate of complete occlusion. However, its safety and efficacy in treatment of large and giant aneurysms has not been evaluated fully.
METHODS: A retrospective analysis of consecutive aneurysms treated with PED between 2009 and 2016 at 3 academic institutions within the United States was performed. Large (≥20 mm) and giant aneurysms (≥25 mm) were selected for evaluation of occlusion and complication rates following treatment with PED.
RESULTS: A total of 50 large and giant aneurysms were individually treated using PED. Aneurysms were fusiform (74%) or saccular (26%) in morphology. PED alone was used for treating 78% of the aneurysms, whereas PED with adjunctive coiling was used for treating 22%. The median length of angiographic follow-up was 13 months (mean follow up 20.4 months). At last follow-up, complete or near-complete occlusion (90-100%) was achieved in 76.9% of aneurysms. Symptomatic thromboembolic complications were encountered in 12% of procedures and symptomatic hemorrhagic complications in 8%.
CONCLUSIONS: The use of PED for the treatment of large and giant intracranial aneurysms is associated with good occlusion rates, but also a greater complication rate compared to aneurysms of smaller size. There was no significant difference in occlusion rate based on aneurysm shape or size, number of PEDs placed, or adjunctive coiling.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Aneurysm; Complications; Giant; Intracranial; Large; Occlusion; Pipeline

Mesh:

Year:  2017        PMID: 28578117     DOI: 10.1016/j.wneu.2017.05.128

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  6 in total

1.  Delayed mesencephalic venous infarction after endovascular treatment of a giant aneurysm of the posterior cerebral artery: Case report and anatomical review.

Authors:  Keisuke Kadooka; Vaia Anagnostakou; Oliver Bozinov; Zsolt Kulcsár
Journal:  Interv Neuroradiol       Date:  2020-09-01       Impact factor: 1.610

2.  Unruptured giant intracavernous aneurysms untolerate internal carotid artery occlusion test: Untreated and treated with flow-diversion.

Authors:  Xianli Lv; Jianjun Yu; Ting Liao; Jin Wang; Guihuai Wang
Journal:  Neuroradiol J       Date:  2020-01-17

3.  Endovascular Treatment of Giant Intracranial Aneurysms.

Authors:  Italo Linfante; Vincenzo Andreone; Natalia Ravelo; Amy K Starosciak; Bilal Arif; Hussain Shallwani; Peter Tze Man Kan; Michael W McDermott; Guilherme Dabus
Journal:  Cureus       Date:  2020-05-26

4.  Possibility of Worsening Flow Diversion Effect Due to Morphological Changes of a Stented Artery With Multiple Overlapping Stents for Partially Thrombosed Vertebral Artery Aneurysms.

Authors:  Tomoaki Suzuki; Hitoshi Hasegawa; Kazuhiro Ando; Kouhei Shibuya; Haruhiko Takahashi; Shoji Saito; Makoto Oishi; Yukihiko Fujii
Journal:  Front Neurol       Date:  2020-12-15       Impact factor: 4.003

5.  Flow Redirection Endoluminal Device (FRED) with or without Adjunctive Coiling in Treatment of Very Large and Giant Cerebral Aneurysms.

Authors:  Sedat Giray Kandemirli; Feyyaz Baltacioglu; Jessica Jesser; Osman Kizilkilic; Civan Islak; Markus Möhlenbruch; Naci Kocer
Journal:  Clin Neuroradiol       Date:  2021-07-26       Impact factor: 3.649

Review 6.  Endovascular Management of Hemorrhagic Stroke.

Authors:  Basel Musmar; Nimer Adeeb; Junaid Ansari; Pankaj Sharma; Hugo H Cuellar
Journal:  Biomedicines       Date:  2022-01-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.